Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL9984539 | 0.87 | CYP1A2 (0.37) | KEAP1CA1CA2CA9CYP1A2 | |
| SCHEMBL31513480 | 0.80 | ALDH1A1 (0.48) | KEAP1CYP1A2 | |
| SCHEMBL1842505 | 0.80 | ALDH1A1 (0.48) | KEAP1CYP1A2 | |
| Water SCHEMBL7550169 | 0.78 | ALDH1A1 (0.46) | KEAP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL146078 | 0.78 | ALDH1A1 (0.46) | KEAP1CYP1A2 | |
| Iodide SCHEMBL28965043 | 0.78 | ALDH1A1 (0.46) | KEAP1CYP1A2 | |
| Fluoride Ion SCHEMBL7552453 | 0.78 | ALDH1A1 (0.46) | KEAP1CYP1A2 | |
| SCHEMBL7546880 | 0.78 | ALDH1A1 (0.46) | KEAP1CYP1A2 | |
| SCHEMBL7546886 | 0.78 | ALDH1A1 (0.50) | KEAP1CYP1A2 | |
| Bromide SCHEMBL11552667 | 0.78 | ALDH1A1 (0.46) | KEAP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114540848-B | Decarboxylation coupling electrocatalytic method for realizing catalysis of aromatic trimethylammonium salt and alpha-nickel ketoacid | 常州工学院 | 2023-09-01 | — | — | CN | claimed |
| US-9205156-B2 | Molecular imaging agents | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2015-12-08 | — | — | US | disclosed |
| US-20110293519-A1 | MOLECULAR IMAGING AGENTS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293519-A1 | MOLECULAR IMAGING AGENTS | TNNI3, FABP3, TNNT2 | GPR3 1260/4885KEAP1 4570/4885CA1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.